Funding Information
Cancer
CANCER
This trial was funded by Cancer Research UK (CRUK/14/041), and supported by Astra Zeneca, who provided Selumetinib and a per-patient grant; Genzyme supplied recombinant TSH. The funders had no role in study design, data collection, data analysis, data interpretation. Astra Zeneca and Sanofi-Genzyme reviewed and approved the final document. The research was developed with support from the National Cancer Research Institute Clinical and Translational Radiotherapy Research Group (NCRI CTRad). The Radiotherapy Trials Quality Assurance Group (RTTQA) is funded by the National Institute for Health Research (NIHR).